ArticleBMC rheumatology2026

Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study.

Masanori Sudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.